900120 — CXI Healthcare Technology Income Statement
0.000.00%
Last trade - 00:00
- KR₩31bn
- -KR₩99bn
- CNY377.03m
- 49
- 100
- 24
- 63
2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 778 | 373 | 610 | 545 | 377 |
Cost of Revenue | |||||
Gross Profit | -37.1 | -67.3 | 127 | 153 | 149 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 1,216 | 964 | 583 | 511 | 340 |
Operating Profit | -438 | -590 | 26.4 | 33.9 | 36.7 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -425 | -580 | 29.7 | 32.2 | 39.6 |
Provision for Income Taxes | |||||
Net Income After Taxes | -425 | -580 | 29.7 | 32.2 | 39.6 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -425 | -579 | 29.7 | 32.2 | 39.6 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -425 | -579 | 29.7 | 31.8 | 39.6 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -3.85 | -3.2 | 0.267 | 0.28 | 0.249 |
Dividends per Share |